ORIC biotech catalysts & pipeline

ORIC PHARMACEUTICALS INC · Data as of 2026-09-08

Upcoming catalysts

enozertinib — Topline data

H2 2026

We expect to report data in the second half of 2026 in 1L NSCLC patients with EGFR exon 20 insertion mutations as a monotherapy and in combination with SC amivantamab, as well as in 1L NSCLC patients with EGFR atypical mutations as a monotherapy.

Source filing

rinzimetostat — Interim data

2H 2026

Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial

Source filing

enozertinib — Conference presentation

Oct 23–Oct 27

− October 2026: 1L EGFR atypical monotherapy data to be presented at ESMO Congress 2026

Source filing

Explore the free biotech catalyst calendar